Resolving the paradigm crisis in intravenous iron and erythropoietin management

Kidney International

Volumn 69, Issue SUPPL. 101, 2006, Pages

  Besarab, A ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Anemia; Continued iron dosing; Erythropoietin; i.v. iron; Iron deficiency; Repletion iron dosing

Indexed keywords

ERYTHROPOIETIN; FERRIC GLUCONATE; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; FERRIC ION;

ALGORITHM; ANEMIA; CLINICAL PROTOCOL; COST CONTROL; DRUG COST; DRUG INDICATION; DRUG SAFETY; FERRITIN BLOOD LEVEL; GASTROINTESTINAL IRRITATION; HEALTH CARE COST; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HORMONAL THERAPY; HUMAN; IRON BALANCE; IRON DEFICIENCY; IRON STORAGE; IRON THERAPY; KIDNEY FAILURE; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TRANSFERRIN BLOOD LEVEL; BLOOD; DOSE RESPONSE; DRUG RESISTANCE; ERYTHROPOIESIS; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; PHYSIOLOGY; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ANEMIA, IRON-DEFICIENCY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; FERRIC COMPOUNDS; FERRITINS; HEMATOCRIT; HEMOGLOBINS; HUMANS; INFLAMMATION; INJECTIONS, INTRAVENOUS; IRON; PRACTICE GUIDELINES; RENAL DIALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 33746488934     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000405     Document Type: Article

References (20)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease. Am J Kidney Dis 2001; 37(Suppl 1): S182-S238.
2. St. Peter WL, Obrador GT, Roberts TL, Collins AJ. Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am J Kidney Dis 2005; 46: 650-660.
3. Fishbane S, Lynn RI. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin Nephrol 1995; 44: 238-240.
4. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68: 1337-1343.
5. Müller-Wiefel DE, Sinn H, Gilli G, Schärer K. Hemolysis and blood loss in children with chronic renal failure. Clin Nephrol 1977; 8: 481-486.
6. Cook JD, Eschbach JW. Iron absorption and loss in chronic renal disease. In: Kief H (ed). Iron Metabolism and Its Disorders. Excerpta Medica International Congress Series No. 366. Excerpta Medica: Amsterdam, Netherlands, 1975, pp 190-198.
7. Besarab A, Frinak S, Yee J. An indistinct balance: the safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 1999; 10: 2029-2043.
8. Canavese C, Grill A, De Costanzi E et al. How to save money for erythropoietin therapy by changing from 'roller coaster' to continuous iron supplementation. Nephron 1999; 81: 362-363.
9. Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 1999; 34: 21-28.
10. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-46.
11. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995; 25: 433-439.
12. Macdougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-1699.
13. Taylor JE, Peat N, Porter C, Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1079-1083.
14. Silverberg DS, Blum M, Peer G et al. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996; 72: 413-417.
15. Suh H, Wadhwa NK. Iron dextran treatment in peritoneal dialysis patients on erythropoietin. Adv Perit Dial 1992; 8: 464-466.
16. Senger JM, Weiss RJ. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. Nephrol Nurs J 1996; 23: 319-323.
17. Bolaños L, Castro P, Falcón TG et al. Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients. Am J Nephrol 2002; 22: 67-72.
18. Macdougall IC, Chandler G, Elston O, Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis 1999; 34(Suppl 2): S40-S46.
19. Harmankaya Ö, Eran A. Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin. Renal Failure 2002; 24: 245-247.
20. Bowe D, Ammel D. Using CQI strategies to improve and simplify IV iron and anemia management, a dialysis facility's experience. Nephrol Nurs J 2005; 32: 535-543.